Related Experiment Video

Updated: Apr 26, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

553

Current status of targeted therapy in non-small cell lung cancer

D V Parums1

  • 1Macclesfield, UK. dvparums@gmail.com.

Drugs of Today (Barcelona, Spain : 1998)
|August 8, 2014
PubMed

Insights

This review covers tumor tissue biomarkers and targeted therapies for non-small cell lung cancer (NSCLC). It details current and emerging targets, companion diagnostics, and ongoing clinical trials for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor tissue biomarkers are crucial for guiding targeted therapy selection in non-small cell lung cancer (NSCLC).
  • Biomarkers can indicate drug targets or factors influencing drug efficacy.
  • Targeted therapies include small-molecule inhibitors and monoclonal antibodies.

Purpose of the Study:

  • To review established and novel tissue biomarkers in NSCLC.
  • To provide an overview of targeted therapies and companion diagnostics.
  • To highlight recent initiatives and upcoming clinical trials in NSCLC targeted therapy.

Main Methods:

  • Literature review of tissue biomarkers in NSCLC.
  • Description of targeted therapies for key molecular targets (e.g., EGFR, HER2, VEGF, ALK, KRAS, BRAF, MET).
  • Overview of companion diagnostics and recent research initiatives.

Main Results:

  • Detailed description of biomarkers and targeted agents for NSCLC.
  • Discussion of targeted therapy for EGF/EGFR, HER2, VEGF/VEGFR, ALK, KRAS, BRAF, MEK, and MET.
  • Mention of initiatives like the Lung Cancer Matrix Network and LCMC.

Conclusions:

  • Biomarker-driven targeted therapy is fundamental in NSCLC treatment.
  • Ongoing research and clinical trials are expanding therapeutic options.
  • Personalized medicine approaches are advancing NSCLC patient care.
Keywords:
BiomarkersEGFRHER2Non-small cell lung cancerTargeted therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
160
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K